ViiV architect Redfern takes up chair post
This article was originally published in Scrip
Executive Summary
David Redfern, GlaxoSmithKline's chief strategy officer, has been appointed the new chairman of ViiV Healthcare, the 85:15 HIV joint venture with Pfizer, which he was closely involved in creating in November 2009. He will succeed Julian Heslop, who retires, and he will start on 1 April. He will continue in his GSK post.